Literature DB >> 626835

Drug treatment of chronic stable angina pectoris.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 626835      PMCID: PMC1603099          DOI: 10.1136/bmj.1.6111.462

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  19 in total

Review 1.  Angina pectoris: getting the most from drug therapy.

Authors:  H B Kay
Journal:  Drugs       Date:  1977-04       Impact factor: 9.546

2.  Assay of anti-anginal agents. I. A curve analysis with multiple control periods.

Authors:  S L COLE; H KAYE; G C GRIFFITH
Journal:  Circulation       Date:  1957-03       Impact factor: 29.690

3.  Proximal myopathy after perhexiline maleate treatment.

Authors:  I W Tomlinson; F D Rosenthal
Journal:  Br Med J       Date:  1977-05-21

Review 4.  Clinical use of verapamil.

Authors:  J K Vohra
Journal:  Drugs       Date:  1977-03       Impact factor: 9.546

Review 5.  Medical treatment of angina pectoris. 8. Miscellaneous antianginal drugs.

Authors:  W S Aronow
Journal:  Am Heart J       Date:  1973-01       Impact factor: 4.749

6.  Medical management of angina pectoris.

Authors:  R B Logue; P H Robinson
Journal:  Circulation       Date:  1972-12       Impact factor: 29.690

Review 7.  Beta-adrenergic receptor blocking drugs in angina pectoris.

Authors:  B N Prichard
Journal:  Drugs       Date:  1974       Impact factor: 9.546

8.  Quantitative evaluation of vitamin E in the treatment of angina pectoris.

Authors:  R E Gillilan; B Mondell; J R Warbasse
Journal:  Am Heart J       Date:  1977-04       Impact factor: 4.749

9.  Double-blind evaluation of verapamil, propranolol, and isosorbide dinitrate against a placebo in the treatment of angina pectoris.

Authors:  B Livesley; P F Catley; R C Campbell; S Oram
Journal:  Br Med J       Date:  1973-02-17

10.  Double-blind comparison of verapamil and practolol in the treatment of angina pectoris.

Authors:  B Fagher; S Persson; S E Svensson
Journal:  Postgrad Med J       Date:  1977-02       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.